- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02522208
Pharmacodynamic and Pharmacokinetic Study of BiDil Extended-release Capsules and Commercial BiDil Tablets
November 7, 2016 updated by: Arbor Pharmaceuticals, Inc.
Randomized, Open-Label, Daily Dose, 2-sequence, 2-way Crossover Pharmacodynamic and Pharmacokinetic Study of BiDil XR Capsules and Commercial BiDil Tablets in Self-identified Black Patients, Who Are Slow Acetylators, With Heart Failure
This study will investigate cardiovascular parameters using echocardiographic and pharmacokinetics during a daily dose of BiDil and BiDil Extended Release (XR) compared to a study drug free day.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A multiple-center, open-label, randomized, daily dose, two-sequence, two-way crossover pharmacodynamics (PD) and pharmacokinetic (PK) study of BiDil XR capsules and commercial BiDil tablets in Self-identified Black Patients, who are Slow Acetylators, with Heart Failure and have not received BiDil, isosorbide dinitrate (ISDN), or hydralazine hydrochloride (HCl) for at least 30 days prior to screening.
The study consists of two doses of BiDil XR capsules (dosed at 0 hr and 9 hr) and three doses of BiDil tablets (dosed at 0 hr, 6 hr and 12 hr).
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Anniston, Alabama, United States, 36207
- Pinnacle Research Group, LLC
-
-
Florida
-
Coral Gables, Florida, United States, 33134
- Linfritz Research Institue Inc
-
Jacksonville, Florida, United States, 32216
- Jacksonville Center for Clinical Research
-
-
Georgia
-
Atlanta, Georgia, United States, 30310
- Morehouse School of Medicine
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02908
- Center for Medical Research, LLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Self-identified Black, stable, chronic heart failure male or female subjects classified as having New York Heart Association (NYHA) Class II or III, diagnosed at least 3 months prior to Screening.
- Clinically stable outpatient, receiving standard, stable treatment regimen for heart failure (HF), at least 2 weeks prior to screening and throughout the duration of the trial. Subjects receiving beta-blockers must have been taking these for at least 3 months.
- All other medications must have been at a stable dose for at least 2 weeks prior to first dose
- Subjects must not have received BiDil, isosorbide dinitrate or hydralazine HCl for at least 30 days prior to Screening
- Have an adequate and demonstrable baseline Tricuspid regurgitation jet, visible inferior vena cava, and adequate right heart echocardiogram (with or without saline bubble contrast) allowing measurements to be made.
- Baseline PA systolic pressures > 35 mmHg
- Slow acetylator
- Adult subjects at least 18 years old or state-specific age of majority.
- Clinical lab tests negative for HIV, Hepatitis B surface antigen and Hepatitis C antibody.
- Urine testing negative for alcohol and drugs of abuse.
- Negative human chorionic gonadotropin (hCG) pregnancy test.
- Females must agree to avoid becoming pregnant or males must agree to use appropriate contraceptive methods with his partner(s), during the study and up to post 30 days from last dose of study drug.
- Females must be:
- unable to have children or
- where the partner is sterile OR
- willing to remain abstinent OR
- willing to use two effective methods of birth control.
- Willing and able to be confined for inpatient study periods and agree to study restrictions
- Ability to grant voluntary informed consent to participate in the study.
Exclusion Criteria:
- Have significant valvular heart disease, hemodynamically significant obstructive hypertrophic cardiomyopathy, active myocarditis, or uncontrolled hypertension.
- Presence of severe, clinical right heart failure.
- Symptoms of unstable angina, a myocardial infarction, cardiac surgery, or percutaneous coronary intervention within 1 month prior to Screening
- Have coronary artery disease likely to require coronary artery bypass grafting or percutaneous coronary intervention during the ensuing 3 months.
- Had cardiac arrest or a sustained ventricular tachycardia considered life threatening and requiring intervention within 3 months, unless treated with implantable cardioverter-defibrillator.
- other causes of pulmonary hypertension that may confound pharmacodynamic assessments of heart failure
- Active malignancy or any non-cardiac life-limiting disease.
- Have significant hepatic, renal, or other disease that might confound the study results or present a risk to the subject.
- Had a stroke within the past 3 months.
- Received parenteral inotropic therapy within 1 month.
- Likelihood of undergoing cardiac transplantation or circulatory assist device implant over the ensuing 3 months.
- Symptomatic hypotension or blood pressure less than 110/70 mmHg at Screening.
- Any condition or risk factor which would jeopardize the evaluation of efficacy or safety or the ability to obtain effective echocardiography results.
- Currently require riociguat, hydralazine HCl, long-acting nitrates like ISDN, isosorbide mononitrate or sustained release nitroglycerin or phosphodiesterase 5 inhibitors.
- Alcohol or drug abuse within 1 year of study participation.
- Hypersensitivity, allergy, idiosyncratic reaction or adverse reaction to caffeine (if slow acetylator test is required), ISDN, hydralazine HCl, or any compounds with similar chemical characteristics.
- Received investigational drug within 30 days.
- Donated one pint or more of blood, plasma, or platelets within 30 days.
- Any subject who, in the opinion of the Investigator, cannot follow instructions.
- Pregnant, lactating or plan to get pregnant during the study
- History of lupus erythematous or lupus like syndrome.
- Use of herbal preparations, grapefruit, grapefruit juice, Seville oranges/juice or use of phosphodiesterase inhibitors within 2 weeks of first dose of study drug and throughout study.
- Employee of the Sponsor, investigative site or contract research organization.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BiDil Extended Release (XR)
BiDil XR isosorbide dinitrate 40 mg and hydralazine hydrochloride 75 mg 2 capsules 9 hours apart for one day
|
fixed combination capsule
Other Names:
fixed combination tablet
Other Names:
|
Active Comparator: BiDil Immediate Release (IR)
BiDil isosorbide dinitrate 20 mg and hydralazine hydrochloride 37.5 mg 3 tablets 6 hours apart for one day
|
fixed combination capsule
Other Names:
fixed combination tablet
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pulmonary Artery (PA) Systolic Pressure change from baseline to each post dose timepoint for 28 hours
Time Frame: 6 days
|
assess the treatment effect of BiDil and BiDil XR on Pulmonary Artery Systolic Pressure (PASP) by Doppler echocardiography
|
6 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of Maximum observed effect (Emax) on PA systolic pressure vs maximum blood concentration (Cmax)
Time Frame: 6 days
|
examine the relationship between the blood concentrations of each active treatment group and the changes in PASP
|
6 days
|
Comparison of the area under the effect curve (AUEC) on PA systolic pressure versus AUC (the area under the curve) for blood
Time Frame: 6 days
|
To examine the relationship between the blood concentrations of each active treatment group and the changes in PASP
|
6 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment effect on ejection fraction
Time Frame: 6 days
|
assessing the treatment effect of BiDil and BiDil XR on other central hemodynamic measures (such as ejection fraction) and examining the relationship between the plasma or blood concentrations of each treatment group and each of these central hemodynamic measure
|
6 days
|
Treatment effect on Mean PA pressure
Time Frame: 6 days
|
assessing the treatment effect of BiDil and BiDil XR on other central hemodynamic measures (such as ejection fraction) and examining the relationship between the plasma or blood concentrations of each treatment group and each of these central hemodynamic measure
|
6 days
|
Treatment effect on PA diastolic pressure
Time Frame: 6 days
|
assessing the treatment effect of BiDil and BiDil XR on other central hemodynamic measures (such as ejection fraction) and examining the relationship between the plasma or blood concentrations of each treatment group and each of these central hemodynamic measure
|
6 days
|
Treatment effect on Pulmonary vascular resistance
Time Frame: 6 days
|
assessing the treatment effect of BiDil and BiDil XR on other central hemodynamic measures (such as ejection fraction) and examining the relationship between the plasma or blood concentrations of each treatment group and each of these central hemodynamic measure
|
6 days
|
Treatment effect on Right atrial pressure
Time Frame: 6 days
|
assessing the treatment effect of BiDil and BiDil XR on other central hemodynamic measures (such as ejection fraction) and examining the relationship between the plasma or blood concentrations of each treatment group and each of these central hemodynamic measure
|
6 days
|
Number of Participants with Adverse Events (AE) as a Measure of Safety and Tolerability
Time Frame: 12 days
|
to compare the safety and tolerability of BiDil XR capsules, as measured by treatment-emergent AEs
|
12 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Steve D Caras, MD, PhD, Arbor Pharmaceuticals
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2015
Primary Completion (Actual)
April 1, 2016
Study Completion (Actual)
April 1, 2016
Study Registration Dates
First Submitted
August 5, 2015
First Submitted That Met QC Criteria
August 11, 2015
First Posted (Estimate)
August 13, 2015
Study Record Updates
Last Update Posted (Estimate)
November 8, 2016
Last Update Submitted That Met QC Criteria
November 7, 2016
Last Verified
November 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Heart Failure
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Natriuretic Agents
- Diuretics, Osmotic
- Diuretics
- Nitric Oxide Donors
- Isosorbide
- Isosorbide Dinitrate
- Isosorbide-5-mononitrate
- Hydralazine
Other Study ID Numbers
- AR06.009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
US Department of Veterans AffairsCompleted
Clinical Trials on BiDil XR
-
University of PittsburghCompletedHeart FailureUnited States
-
Eisai Inc.Terminated
-
UCB PharmaCompletedEpilepsyUnited States, Poland, Mexico, Russian Federation
-
Coopervision, Inc.CompletedMyopia | HyperopiaUnited States, Canada
-
Supernus Pharmaceuticals, Inc.Completed
-
FUSMobile Inc.Active, not recruitingFacet Syndrome of Lumbar SpineCanada
-
Envisia TherapeuticsCompletedGlaucoma and Ocular HypertensionUnited States
-
Meir Medical CenterUnknownSubchondral Fractures of the Glenoid
-
Upsher-Smith LaboratoriesRecruitingMigraine DisordersUnited States